ATE458732T1 - Verwendung von 4-imidazol-derivaten für zns- erkrankungen - Google Patents
Verwendung von 4-imidazol-derivaten für zns- erkrankungenInfo
- Publication number
- ATE458732T1 ATE458732T1 AT07703939T AT07703939T ATE458732T1 AT E458732 T1 ATE458732 T1 AT E458732T1 AT 07703939 T AT07703939 T AT 07703939T AT 07703939 T AT07703939 T AT 07703939T AT E458732 T1 ATE458732 T1 AT E458732T1
- Authority
- AT
- Austria
- Prior art keywords
- imidazole derivatives
- cns diseases
- cns
- diseases
- imidazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06100938 | 2006-01-27 | ||
PCT/EP2007/050441 WO2007085556A2 (en) | 2006-01-27 | 2007-01-17 | Use of 4-imidazole derivatives for cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE458732T1 true ATE458732T1 (de) | 2010-03-15 |
Family
ID=38051581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07703939T ATE458732T1 (de) | 2006-01-27 | 2007-01-17 | Verwendung von 4-imidazol-derivaten für zns- erkrankungen |
Country Status (18)
Country | Link |
---|---|
US (1) | US8158668B2 (de) |
EP (1) | EP1981880B1 (de) |
JP (1) | JP2009524616A (de) |
KR (1) | KR101079914B1 (de) |
CN (1) | CN101374832B (de) |
AR (1) | AR059206A1 (de) |
AT (1) | ATE458732T1 (de) |
AU (1) | AU2007209380B2 (de) |
BR (1) | BRPI0706759A2 (de) |
CA (1) | CA2637308C (de) |
DE (1) | DE602007004949D1 (de) |
ES (1) | ES2338716T3 (de) |
IL (1) | IL192885A0 (de) |
NO (1) | NO20083356L (de) |
RU (1) | RU2008130448A (de) |
TW (1) | TW200738645A (de) |
WO (1) | WO2007085556A2 (de) |
ZA (1) | ZA200806457B (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1981497A2 (de) | 2006-01-27 | 2008-10-22 | F.Hoffmann-La Roche Ag | Verwendung von substituiertem 2-imidazol aus imidazolin-derivaten |
EP2076497B1 (de) | 2006-10-19 | 2012-02-22 | F. Hoffmann-La Roche AG | Aminomethyl-4-imidazole |
MX2009008255A (es) | 2007-02-02 | 2009-08-12 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos taar1. |
MX2009008776A (es) * | 2007-02-13 | 2009-08-25 | Schering Corp | Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos. |
CA2678036A1 (en) | 2007-02-13 | 2008-08-21 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
EP2142538B1 (de) | 2007-02-13 | 2011-10-26 | Schering Corporation | Derivate und analoge von chroman als funktionell selektive alpha2c-adrenorezeptor-agonisten |
WO2009003867A1 (en) * | 2007-07-03 | 2009-01-08 | F. Hoffmann-La Roche Ag | 4-imidazolines and their use as antidepressants |
US7902247B2 (en) | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
AU2009205539B2 (en) * | 2008-01-18 | 2013-12-05 | Allergan.Inc | Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
CN102083805A (zh) * | 2008-07-24 | 2011-06-01 | 弗·哈夫曼-拉罗切有限公司 | 4,5-二氢-唑-2-基衍生物 |
US20120190719A1 (en) * | 2009-08-26 | 2012-07-26 | Allergan, Inc. | Methods of treating motor disorders with alpha-2b andrenergic receptor agonists |
AR077969A1 (es) | 2009-08-31 | 2011-10-05 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina comomoduladores de s1p |
US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
TWI543984B (zh) | 2010-07-09 | 2016-08-01 | 艾伯維公司 | 作為s1p調節劑的螺-哌啶衍生物 |
AR090557A1 (es) | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
AU2014229313B2 (en) | 2013-03-14 | 2016-07-28 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
KR101948779B1 (ko) | 2013-10-07 | 2019-05-21 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법 |
JP6310070B2 (ja) * | 2013-10-07 | 2018-04-11 | テイコク ファーマ ユーエスエー インコーポレーテッド | デクスメデトミジン経皮組成物を用いる、注意欠陥多動性障害、不安症及び不眠症の治療法及び組成物 |
CN103664788B (zh) * | 2013-12-04 | 2015-11-25 | 湖北生物医药产业技术研究院有限公司 | 制备美托咪啶的方法 |
US10189844B2 (en) | 2016-02-04 | 2019-01-29 | Chiesi Farmaceutici S.P.A. | Pyrazole derivatives as phosphoinositide 3-kinases inhibitors |
EP3757102A1 (de) | 2016-03-17 | 2020-12-30 | F. Hoffmann-La Roche AG | 5-ethyl-4-methyl-pyrazole-3-carboxamid-derivat mit wirkung als taar agonist |
CN105884691B (zh) * | 2016-06-02 | 2017-08-25 | 江苏恒瑞医药股份有限公司 | 一种制备右美托咪定及其中间体的方法 |
JP7343170B2 (ja) * | 2017-05-12 | 2023-09-12 | ボード オブ トラスティーズ オブ ザ サザン イリノイ ユニバーシティ オン ビハーフ オブ サザン イリノイ ユニバーシティ エドワーズビル | 3,4,5-三置換-1,2,4-トリアゾールおよび3,4,5-三置換-3-チオ-1,2,4-トリアゾール、ならびにそれらの使用 |
CN107879979B (zh) * | 2017-10-27 | 2020-08-25 | 广东莱佛士制药技术有限公司 | 一种右美托咪定的制备方法 |
MX2022005084A (es) | 2019-10-31 | 2022-05-26 | Escape Bio Inc | Formas sólidas de un modulador del receptor s1p a. |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7312245A (nl) * | 1973-09-06 | 1975-03-10 | Stamicarbon | Werkwijze voor het bereiden van alphamethylstyreen bevattende blokcopolymeren. |
AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
GB2101114B (en) * | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
JPH0733333B2 (ja) * | 1986-12-12 | 1995-04-12 | 三井石油化学工業株式会社 | 脳機能改善薬 |
GB2215206B (en) * | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
FI894911A0 (fi) * | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
GB2256135B (en) | 1991-05-31 | 1995-01-18 | Orion Yhtymae Oy | Transdermal administration of 4-substituted imidazoles |
GB9521680D0 (en) | 1995-10-23 | 1996-01-03 | Orion Yhtymo Oy | New use of imidazole derivatives |
AU744798B2 (en) * | 1997-12-04 | 2002-03-07 | Allergan, Inc. | Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
JP4546589B2 (ja) * | 1998-04-23 | 2010-09-15 | 武田薬品工業株式会社 | ナフタレン誘導体 |
ATE293102T1 (de) * | 1998-04-23 | 2005-04-15 | Takeda Pharmaceutical | Naphthalene derivate ,ihre herstellung und verwendung |
JP4520012B2 (ja) * | 1999-10-22 | 2010-08-04 | 武田薬品工業株式会社 | 1−置換−1−(1h−イミダゾール−4−イル)メタノール類 |
PE20010781A1 (es) * | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
MXPA06000269A (es) * | 2003-07-09 | 2006-04-07 | Hoffmann La Roche | Tiofenilaminoimidazolinas. |
AU2004279336A1 (en) * | 2003-09-12 | 2005-04-21 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
MX2007003068A (es) * | 2004-09-24 | 2007-05-21 | Allergan Inc | 4-(fenil-metil y fenil-metil substituido)-imidazol-2tionas como agonistas adrenergicos alfa2 especificos. |
-
2007
- 2007-01-17 CA CA2637308A patent/CA2637308C/en not_active Expired - Fee Related
- 2007-01-17 ES ES07703939T patent/ES2338716T3/es active Active
- 2007-01-17 BR BRPI0706759-3A patent/BRPI0706759A2/pt not_active IP Right Cessation
- 2007-01-17 JP JP2008551759A patent/JP2009524616A/ja active Pending
- 2007-01-17 RU RU2008130448/04A patent/RU2008130448A/ru not_active Application Discontinuation
- 2007-01-17 DE DE602007004949T patent/DE602007004949D1/de active Active
- 2007-01-17 WO PCT/EP2007/050441 patent/WO2007085556A2/en active Application Filing
- 2007-01-17 KR KR1020087020817A patent/KR101079914B1/ko not_active IP Right Cessation
- 2007-01-17 CN CN2007800036567A patent/CN101374832B/zh not_active Expired - Fee Related
- 2007-01-17 AT AT07703939T patent/ATE458732T1/de active
- 2007-01-17 EP EP07703939A patent/EP1981880B1/de not_active Not-in-force
- 2007-01-17 AU AU2007209380A patent/AU2007209380B2/en not_active Ceased
- 2007-01-19 US US11/655,539 patent/US8158668B2/en not_active Expired - Fee Related
- 2007-01-25 TW TW096102837A patent/TW200738645A/zh unknown
- 2007-01-26 AR ARP070100342A patent/AR059206A1/es unknown
-
2008
- 2008-07-17 IL IL192885A patent/IL192885A0/en unknown
- 2008-07-24 ZA ZA200806457A patent/ZA200806457B/xx unknown
- 2008-07-31 NO NO20083356A patent/NO20083356L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2007209380A1 (en) | 2007-08-02 |
NO20083356L (no) | 2008-10-21 |
ES2338716T3 (es) | 2010-05-11 |
JP2009524616A (ja) | 2009-07-02 |
KR101079914B1 (ko) | 2011-11-04 |
WO2007085556A3 (en) | 2007-10-04 |
US8158668B2 (en) | 2012-04-17 |
CN101374832B (zh) | 2013-03-06 |
IL192885A0 (en) | 2009-02-11 |
DE602007004949D1 (de) | 2010-04-08 |
ZA200806457B (en) | 2009-11-25 |
EP1981880A2 (de) | 2008-10-22 |
CA2637308C (en) | 2014-02-25 |
CA2637308A1 (en) | 2007-08-02 |
WO2007085556A2 (en) | 2007-08-02 |
KR20080088658A (ko) | 2008-10-02 |
EP1981880B1 (de) | 2010-02-24 |
BRPI0706759A2 (pt) | 2011-04-05 |
TW200738645A (en) | 2007-10-16 |
CN101374832A (zh) | 2009-02-25 |
AR059206A1 (es) | 2008-03-19 |
AU2007209380B2 (en) | 2011-12-08 |
RU2008130448A (ru) | 2010-03-10 |
US20070197622A1 (en) | 2007-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE458732T1 (de) | Verwendung von 4-imidazol-derivaten für zns- erkrankungen | |
DE602005021132D1 (de) | Ausgabeeinheit für Wertscheine | |
DK1940839T3 (da) | Pyridopyrimidione Inhibitors of P13Ka | |
DE602006015297D1 (de) | 3-azetidincarbonsäure-derivate zur verwendung als immunsuppressiva | |
DOP2007000084A (es) | Derivados de dihidropirazolopirimidinona | |
DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
BRPI0719389A2 (pt) | Derivados de hidantoína utilizados como inibidores de mmp | |
CR10562A (es) | Nuevos derivados de piridazina | |
CY2016017I2 (el) | Συνθεση για θεραπεια πνευμονικης υπερτασης | |
CU23828B1 (es) | Derivados de dihidropiridina de utilidad como inhibodires de la proteína quinasa | |
DK1874781T3 (da) | Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme | |
MA32551B1 (fr) | Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires | |
DE602006011363D1 (de) | Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer | |
ATE528296T1 (de) | Polymorphe form von 4-ä3-(4- cyclopropancarbonylpiperazin-1-carbonyl)-4- fluorbenzylü-2h-phthalazin-1-on | |
DK1916890T3 (da) | Forbedrede egenskaber for græsendofytter | |
FI20065757A (fi) | Beta-laktamaasin käyttö | |
DE112007000789A5 (de) | Verwendung von Bora-tetraazepentalenen | |
FI20075600A0 (fi) | Komponentin eliniän määritys | |
ATE552753T1 (de) | Ausziehführung für schubladen | |
ATE469150T1 (de) | Kristallformen eines imidazolderivats | |
NO20091266L (no) | Fremgangsmåter for administrering av langvarige hypoglykemiske midler | |
NO20083328L (no) | Fremgangsmåte for fremstilling av papir | |
FI20075505A (fi) | Menetelmä silmälasien valmistamiseksi | |
CR10809A (es) | Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona | |
ATE443991T1 (de) | Verwendung von phenylsemicarbazonen für die saatgutbeizung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1981880 Country of ref document: EP |